FUMARIC ACID ESTERS - A THERAPEUTIC OPTION IN PLAQUE PSORIASIS

  • Leonor Lopes Interna do Internato complementar de Dermatologia da Clínica Universitária de Dermatologia/ Resident of Dermatology and Venereology of Lisbon University
  • Ana Isabel Gouveia Interna do Internato complementar de Dermatologia da Clínica Universitária de Dermatologia/ Resident of Dermatology and Venereology of Lisbon University
  • Paulo Leal Filipe Professor de Dermatologia e Venereologia da Clínica Universitária de Dermatologia/Professor of Dermatology and Venereology of Lisbon University
Keywords: Fumarates, Psoriasis

Abstract

Fumaric acid esters are licensed for the treatment of psoriasis in Germany, since 1994. They are effective, safe and economical when compared with other systemic therapies used in moderate to severe plaque-type psoriasis. Fumarate esters have promising potential not only for the treatment of psoriasis but also for other less frequent dermatological conditions. The aim of this article is to review the mechanisms of action, indications and contraindications for this therapy.

Downloads

Download data is not yet available.

References

Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005;

:43-48.

Meissner M, Valesky EM, Kippenberger S, Kaufmann R. Dimethyl fumarate - only an anti-psoriatic medication? J Dtsch Dermatol Ges. 2012; 10:793-801.

Hoefnagel JJ, Thio HB, Willemze R, Bavinck JNB. Therapeutics Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003; 149(2):363-9.

Moharregh-Khiabani D, Linker R, Gold R, Stangel M. Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol. 2009; 7:60-4.

Breuer K, Gutzmer R, Völker B, Kapp A, Werfel T. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol. 2005; 152:1290-5.

Walker F, Adamczyk A, Kellerer C, Belge K, Brück J, Berner T, et al. Fumaderm® in daily practice for psoriasis:

dosing, efficacy and quality of life. Br J Dermatol. 2014; 171:1197-1205.

Boer A, Roll A, Reich K. Use of fumaric acid esters in psoriasis. Indian J Dermatol Venereol Leprol. 2007; 73:133.

Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol. 2010; 162):427-34.

Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, et al. Antipsoriasis effect of fumaric acid

derivatives: Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994; 30:977-81.

Fallah Arani S, Neumann H, Hop WC, Thio HB. Fumantes vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol. 2011; 164:855-61.

Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exper Dermatol. 2007;

:246-9.

Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venerol. 1995; 4:35-40.

Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S. Fumaric acid esters in the treatment of psoriasis: an

Italian experience. J Dermatol Treat. 2004; 15:23-6.

Systemic treatment of psoriasis vulgaris. European Dermatology forum (2012). [consultado 9 Junho de 2015]. Disponível em: http://www.google.pt/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CCUQFjABahU

KEwjQiuu5m43GAhVLQBQKHWR2ADo&url=http%3A%2F%2Fwww.euroderm.org%2Fedf%2Findex.php%2Fedf-

-guidelines%2Fcategory%2F5-guidelines-miscellaneous%3Fdownload%3D32%3Aguideline-psoriasis&ei=-

-Gp8VdCuEMuAUeTsgdAD&usg=AFQjCNHLF9cNLXl11ltPT51TyncHKtkoyQ&sig2=zOawpxuIQN4E77zg-

-Zf6CA&bvm=bv.95515949,d.d24.

Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol. 2004; 150:741-6.

Schmitt J, Zhang Z, Wozel G, Meurer M and Kirch W. Efficacy and tolerability of biologic and non biologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008; 159:513-26.

Fumaderm®: what is the evidence for its efficacy and safety in treating psoriasis? UK Medicines Information

(UKMi) pharmacists for NHS healthcare professionals. Oct 2013. [consultado 9 Junho de 2015]. Disponível

em: http://www.google.pt/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CCUQFjABahUKEwiWmZL7

ozGAhUDOxQKHW1tAAw&url=http%3A%2F%2Fwww.medicinesresources.nhs.uk%2Fupload%2Fdocuments%2

FEvidence%2FMedicines%2520Q%2520%26%2520A%2FNW%2520QA246.2%2520Fumaderm%2520for%252

psoriasis.doc&ei=7jN8VZbqCIP2UO3agWA&usg=AFQjCNHH9fr6tud5d8FHdnhKk8mgUcytJw&sig2=sLTRg2

BH0H2wHFyYYbmUSA&bvm=bv.95515949,d.ZGU.

Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol. 2004;

:630-2.

Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br J Dermatol. 1998; 138:456-60.

Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58

cases. Br J Dermatol. 2005; 153:549-51.

Van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattles MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368:1658-9.

Gerdes S, Domm S, Mrowietz U. Long-term treatment with fumaric acid esters in an 11-year old male child with psoriasis. Dermatology. 2011; 222:198-200.

Balak DM, Oostveen AM, Bousema MT, Venema AW, Arnold WP, Seyger MM, et al. Effectiveness and safety of

fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from the Netherlands. Br J

Dermatol.2013; 168:1343-7.

Eberle FC, Ghoreschi K, Hertl M. Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report

and evaluation of current therapies. Acta Derm Venereol. 2010; 90104-6.

Venten I, Hess N, Hirschmüller A, Altmeyer P, Brockmeyer N. Treatment of therapy - resistant alopecia aerate with fumaric acid esters. Eur J Med Res. 2006; 11:300-5.

Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis:

an assessment of the benefits and risks. Br J Dermatol. 2005; 152:597-615.

Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000; 4:1-125.

NIHR Horizon Scanning Centre. Dimethyl fumarate for plaque psoriasis. 2013 [consultado 9 Junho de 2015].

Disponível: http://www.hsc.nihr.ac.uk.

Thaci D, Weisenseel P, Phillipp S, Rosenbach T, Rotterdam S, Augustin M, et al. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS). J Dtsch Dermatol Ges. 2013; 11:429-36.

Fika Z, Williams RE, Williamson DJ. Fumaric acid esters in psoriasis. Br J Dermatol. 2006; 154:567-8.

Published
2015-09-29
How to Cite
Lopes, L., Gouveia, A. I., & Leal Filipe, P. (2015). FUMARIC ACID ESTERS - A THERAPEUTIC OPTION IN PLAQUE PSORIASIS. Journal of the Portuguese Society of Dermatology and Venereology, 73(3), 353-357. https://doi.org/10.29021/spdv.73.3.458
Section
Review Articles